诺华-话题@MedSci

#诺华#

235篇内容 | 5212人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1282813, encodeId=379e128281311, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华制药与中国县域医院院长联盟达成战略合作，共促县域医疗卫生整体发展, objectType=article, longId=200307, objectId=59ee20030ecf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59ee20030ecf, replyNumber=0, likeNumber=38, createdTime=2020-09-07, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59ee20030ecf, moduleTitle=诺华制药与中国县域医院院长联盟达成战略合作，共促县域医疗卫生整体发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59ee20030ecf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282812, encodeId=23091282812ab, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=NEJM：诺华每月注射一次的奥法木单抗ofatumumab在多发性硬化症患者中展现优越疗效, objectType=article, longId=198891, objectId=c95419889159, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c95419889159, replyNumber=0, likeNumber=79, createdTime=2020-08-08, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c95419889159, moduleTitle=NEJM：诺华每月注射一次的奥法木单抗ofatumumab在多发性硬化症患者中展现优越疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c95419889159)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282811, encodeId=56d91282811ce, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华CAR-T疗法Kymriah：达到滤泡性淋巴瘤试验终点, objectType=article, longId=198822, objectId=494f19882295, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=494f19882295, replyNumber=0, likeNumber=76, createdTime=2020-08-07, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=494f19882295, moduleTitle=诺华CAR-T疗法Kymriah：达到滤泡性淋巴瘤试验终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=494f19882295)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282810, encodeId=15d412828106a, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华IL-17A单抗Cosentyx：获欧盟批准一线治疗牛皮癣儿童患者, objectType=article, longId=198732, objectId=59fb198e32ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59fb198e32ce, replyNumber=0, likeNumber=98, createdTime=2020-08-06, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59fb198e32ce, moduleTitle=诺华IL-17A单抗Cosentyx：获欧盟批准一线治疗牛皮癣儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59fb198e32ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282809, encodeId=33df12828099a, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, objectType=article, longId=197732, objectId=5be919e73267, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5be919e73267, replyNumber=0, likeNumber=60, createdTime=2020-07-20, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5be919e73267, moduleTitle=牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5be919e73267)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282808, encodeId=8e161282808b4, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=FDA批准诺华的IL-17A单抗Cosytyx，用于治疗非放射线轴性脊柱关节炎, objectType=article, longId=196068, objectId=36e6196068e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36e6196068e4, replyNumber=0, likeNumber=64, createdTime=2020-06-19, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36e6196068e4, moduleTitle=FDA批准诺华的IL-17A单抗Cosytyx，用于治疗非放射线轴性脊柱关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36e6196068e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282807, encodeId=a6c3128280ed1, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=FDA批准Still病的**药物：诺华的白细胞介素-1单抗canakinumab, objectType=article, longId=196063, objectId=e34d196063ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e34d196063ce, replyNumber=0, likeNumber=89, createdTime=2020-06-19, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e34d196063ce, moduleTitle=FDA批准Still病的**药物：诺华的白细胞介素-1单抗canakinumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e34d196063ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282806, encodeId=81101282806a2, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎, objectType=article, longId=195329, objectId=e84519532957, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e84519532957, replyNumber=0, likeNumber=76, createdTime=2020-06-06, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e84519532957, moduleTitle=诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e84519532957)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282805, encodeId=9a10128280574, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华的天价基因疗法Zolgensma，在欧洲获批治疗脊柱性肌肉萎缩症, objectType=article, longId=194459, objectId=50e81944593f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50e81944593f, replyNumber=0, likeNumber=67, createdTime=2020-05-22, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50e81944593f, moduleTitle=诺华的天价基因疗法Zolgensma，在欧洲获批治疗脊柱性肌肉萎缩症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50e81944593f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282804, encodeId=2d27128280413, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=FDA加速批准诺华的MET抑制剂Tabrecta，用于治疗METex14突变的转移性非小细胞肺癌, objectType=article, longId=193801, objectId=4a9d19380176, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a9d19380176, replyNumber=0, likeNumber=36, createdTime=2020-05-10, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a9d19380176, moduleTitle=FDA加速批准诺华的MET抑制剂Tabrecta，用于治疗METex14突变的转移性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a9d19380176)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282803, encodeId=b9e812828037c, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=2020 Q1各大药企收入排名，强生，罗氏，诺华，默沙东，辉瑞，礼来，阿斯利康......, objectType=article, longId=193435, objectId=cdbc1934355a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdbc1934355a, replyNumber=0, likeNumber=94, createdTime=2020-05-05, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdbc1934355a, moduleTitle=2020 Q1各大药企收入排名，强生，罗氏，诺华，默沙东，辉瑞，礼来，阿斯利康......, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdbc1934355a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282802, encodeId=5fae1282802fb, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=欧洲药品管理局：支持诺华的Enerzair Breezhaler三联疗法治疗不受控制的哮喘, objectType=article, longId=193381, objectId=964219338183, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=964219338183, replyNumber=0, likeNumber=84, createdTime=2020-05-04, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=964219338183, moduleTitle=欧洲药品管理局：支持诺华的Enerzair Breezhaler三联疗法治疗不受控制的哮喘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=964219338183)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282801, encodeId=ca64128280147, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=欧盟批准诺华的IL-17单抗Cosentyx，用于治疗非放射线轴性脊柱关节炎, objectType=article, longId=193367, objectId=384819336e00, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=384819336e00, replyNumber=0, likeNumber=97, createdTime=2020-05-03, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=384819336e00, moduleTitle=欧盟批准诺华的IL-17单抗Cosentyx，用于治疗非放射线轴性脊柱关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=384819336e00)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282800, encodeId=5015128280003, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=IL-6试验令人失望后，诺华将测试IL-1单抗canakinumab用于抵抗新冠COVID-19的细胞因子风暴, objectType=article, longId=193314, objectId=6b1119331457, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b1119331457, replyNumber=0, likeNumber=0, createdTime=2020-05-03, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b1119331457, moduleTitle=IL-6试验令人失望后，诺华将测试IL-1单抗canakinumab用于抵抗新冠COVID-19的细胞因子风暴, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b1119331457)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282799, encodeId=c66b1282e9921, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华宣布向瑞士捐赠羟氯喹, objectType=article, longId=191601, objectId=84ec19160182, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84ec19160182, replyNumber=0, likeNumber=69, createdTime=2020-04-08, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84ec19160182, moduleTitle=诺华宣布向瑞士捐赠羟氯喹, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84ec19160182)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282798, encodeId=7efe1282e98fc, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华的基因疗法Zolgensma，在日本获批治疗脊髓性肌萎缩症（SMA）儿童患者, objectType=article, longId=190503, objectId=eb4819050376, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb4819050376, replyNumber=0, likeNumber=71, createdTime=2020-03-22, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb4819050376, moduleTitle=诺华的基因疗法Zolgensma，在日本获批治疗脊髓性肌萎缩症（SMA）儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb4819050376)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282797, encodeId=69841282e977d, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=英国首位患者在NHS内接受诺华的Luxturna基因疗法治疗先天性黑蒙病, objectType=article, longId=188484, objectId=ca9118848477, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca9118848477, replyNumber=0, likeNumber=61, createdTime=2020-02-22, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca9118848477, moduleTitle=英国首位患者在NHS内接受诺华的Luxturna基因疗法治疗先天性黑蒙病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca9118848477)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282796, encodeId=775b1282e96bd, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华的抗血管内皮生长因子（VEGF）单抗Beovu获欧盟批准，用于治疗年龄相关的湿性黄斑变性, objectType=article, longId=188479, objectId=2f351884e941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f351884e941, replyNumber=0, likeNumber=67, createdTime=2020-02-22, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f351884e941, moduleTitle=诺华的抗血管内皮生长因子（VEGF）单抗Beovu获欧盟批准，用于治疗年龄相关的湿性黄斑变性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f351884e941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282795, encodeId=d0ad1282e9548, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华的MET抑制剂卡马替尼治疗非小细胞肺癌，获得FDA授予优先审查, objectType=article, longId=188056, objectId=35e3188056f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35e3188056f8, replyNumber=0, likeNumber=89, createdTime=2020-02-16, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35e3188056f8, moduleTitle=诺华的MET抑制剂卡马替尼治疗非小细胞肺癌，获得FDA授予优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35e3188056f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282794, encodeId=666c1282e94ac, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华2019年财报：Consetyx销售额居首，基因治疗未来可期, objectType=article, longId=187082, objectId=02c618e082ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02c618e082ff, replyNumber=0, likeNumber=88, createdTime=2020-02-02, rootId=0, userName=nian.wang1982, userId=6f63175, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02c618e082ff, moduleTitle=诺华2019年财报：Consetyx销售额居首，基因治疗未来可期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02c618e082ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

诺华

2020-05-29发表于威斯康星

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华制药与中国县域医院院长联盟达成战略合作，共促县域医疗卫生整体发展

2020-09-07

仁心济世 (审核中...)

前往app查看评论内容

#诺华#

NEJM：诺华每月注射一次的奥法木单抗ofatumumab在多发性硬化症患者中展现优越疗效

2020-08-08

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华CAR-T疗法Kymriah：达到滤泡性淋巴瘤试验终点

2020-08-07

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华IL-17A单抗Cosentyx：获欧盟批准一线治疗牛皮癣儿童患者

2020-08-06

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

牛皮癣III期临床：礼来的IL-23单抗mirikizumab优于诺华的IL-17A单抗Cosentyx

2020-07-20

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

FDA批准诺华的IL-17A单抗Cosytyx，用于治疗非放射线轴性脊柱关节炎

2020-06-19

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

FDA批准Still病的**药物：诺华的白细胞介素-1单抗canakinumab

2020-06-19

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎

2020-06-06

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华的天价基因疗法Zolgensma，在欧洲获批治疗脊柱性肌肉萎缩症

2020-05-22

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

FDA加速批准诺华的MET抑制剂Tabrecta，用于治疗METex14突变的转移性非小细胞肺癌

2020-05-10

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

2020 Q1各大药企收入排名，强生，罗氏，诺华，默沙东，辉瑞，礼来，阿斯利康......

2020-05-05

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

欧洲药品管理局：支持诺华的Enerzair Breezhaler三联疗法治疗不受控制的哮喘

2020-05-04

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

欧盟批准诺华的IL-17单抗Cosentyx，用于治疗非放射线轴性脊柱关节炎

2020-05-03

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

IL-6试验令人失望后，诺华将测试IL-1单抗canakinumab用于抵抗新冠COVID-19的细胞因子风暴

2020-05-03

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华宣布向瑞士捐赠羟氯喹

2020-04-08

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华的基因疗法Zolgensma，在日本获批治疗脊髓性肌萎缩症（SMA）儿童患者

2020-03-22

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

英国首位患者在NHS内接受诺华的Luxturna基因疗法治疗先天性黑蒙病

2020-02-22

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华的抗血管内皮生长因子（VEGF）单抗Beovu获欧盟批准，用于治疗年龄相关的湿性黄斑变性

2020-02-22

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华的MET抑制剂卡马替尼治疗非小细胞肺癌，获得FDA授予优先审查

2020-02-16

nian.wang1982 (审核中...)

前往app查看评论内容

#诺华#

诺华2019年财报：Consetyx销售额居首，基因治疗未来可期

2020-02-02

科室
- - 订阅+
  - 更多科室
工具
服务